Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 194

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects

Open access
Bouter, K EC, Bakker, G J, Levin, E., Hartstra, A V, Kootte, R S, Udayappan, S D, Katiraei, S., Bahler, L., Gilijamse, P. W., Tremaroli, V., Stahlman, M., Holleman, F., van Riel, N. A. W., Verberne, H J, Romijn, J A, Dallinga-Thie, G M, Serlie, M J, Ackermans, M T, Kemper, E M, van Dijk, Willems K., Backhed, F., Groen, A K, Nieuwdorp, M. · 2018 · Clinical and Translational Gastroenterology

Abstract

Background: Gut microbiota-derived short-chain fatty acids (SCFAs) have been associated with beneficial metabolic effects. However, the direct effect of oral butyrate on metabolic parameters in humans has never been studied. In this first in men pilot study, we thus treated both lean and metabolic syndrome male subjects with oral sodium butyrate and investigated the effect on metabolism. Methods: Healthy lean males (n = 9) and metabolic syndrome males (n = 10) were treated with oral 4 g of sodium butyrate daily for 4 weeks. Before and after treatment, insulin sensitivity was determined by a two-step hyperinsulinemic euglycemic clamp using [6,6-2H2]-glucose. Brown adipose tissue (BAT) uptake of glucose was visualized using 18F-FDG PET-CT. Fecal SCFA and bile acid concentrations as well as microbiota composition were determined before and after treatment. Results: Oral butyrate had no effect on plasma and fecal butyrate levels after treatment, but did alter other SCFAs in both plasma and feces. Moreover, only in healthy lean subjects a significant improvement was observed in both peripheral (median Rd: from 71 to 82 μmol/kg min, p < 0.05) and hepatic insulin sensitivity (EGP suppression from 75 to 82% p < 0.05). Although BAT activity was significantly higher at baseline in lean (SUVmax: 12.4 ± 1.8) compared with metabolic syndrome subjects (SUVmax: 0.3 ± 0.8, p < 0.01), no significant effect following butyrate treatment on BAT was observed in either group (SUVmax lean to 13.3 ± 2.4 versus metabolic syndrome subjects to 1.2 ± 4.1). Conclusions: Oral butyrate treatment beneficially affects glucose metabolism in lean but not metabolic syndrome subjects, presumably due to an altered SCFA handling in insulin-resistant subjects. Although preliminary, these first in men findings argue against oral butyrate supplementation as treatment for glucose regulation in human subjects with type 2 diabetes mellitus.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41424-018-0025-4

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 194

Metadata

Authors
Bouter, K. E., Bakker, G. J., Levin, E., Hartstra, A. V., Kootte, R. S., Udayappan, S. D., Katiraei, S., Bahler, L., Gilijamse, P. W., Tremaroli, V., Stahlman, M., Holleman, F., van Riel, N. A. W., Verberne, H. J., Romijn, J. A., Dallinga-Thie, G. M., Serlie, M. J., Ackermans, M. T., Kemper, E. M., van Dijk, W. K., Backhed, F., Groen, A. K., & Nieuwdorp, M.
Venue
Clinical and Translational Gastroenterology
Published
2018-05
Volume
9
Issue
5
Pages
e155
ISSN
2155-384X (ISSN-L)
OpenAlex
W2803279161
Cited by
194
References
19
FWCI
5.89
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. https://app.cochat.ai/papers/10.1038/s41424-018-0025-4
The paper
Bouter, K. E., Bakker, G. J., Levin, E., Hartstra, A. V., Kootte, R. S., Udayappan, S. D., Katiraei, S., Bahler, L., Gilijamse, P. W., Tremaroli, V., Stahlman, M., Holleman, F., van Riel, N. A. W., Verberne, H. J., Romijn, J. A., Dallinga-Thie, G. M., Serlie, M. J., Ackermans, M. T., Kemper, E. M., . . . Nieuwdorp, M. (2018). Differential metabolic effects of oral butyrate treatment in lean versus metabolic syndrome subjects. Clinical and Translational Gastroenterology. https://doi.org/10.1038/s41424-018-0025-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.